APA (7th ed.) Citation

P, D. d. R., L, L., A, M., LB, A., H, M., L, F., . . . E, L. (2024). A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer, 12(1), . https://doi.org/10.1136/jitc-2023-007135

Chicago Style (17th ed.) Citation

P, Desroys du Roure, et al. "A Novel Fc-engineered Cathepsin D-targeting Antibody Enhances ADCC, Triggers Tumor-infiltrating NK Cell Recruitment, and Improves Treatment with Paclitaxel and Enzalutamide in Triple-negative Breast Cancer." Journal for Immunotherapy of Cancer 12, no. 1 (2024). https://doi.org/10.1136/jitc-2023-007135.

MLA (9th ed.) Citation

P, Desroys du Roure, et al. "A Novel Fc-engineered Cathepsin D-targeting Antibody Enhances ADCC, Triggers Tumor-infiltrating NK Cell Recruitment, and Improves Treatment with Paclitaxel and Enzalutamide in Triple-negative Breast Cancer." Journal for Immunotherapy of Cancer, vol. 12, no. 1, 2024, https://doi.org/10.1136/jitc-2023-007135.